PO.MCB05.01 · 分子与细胞生物学

BRCT结构域是DNA损伤反应中信号转导的模块化平台

The BRCT domain is a modular platform for signal transduction in the DNA damage response

海报缩略图:BRCT结构域是DNA损伤反应中信号转导的模块化平台
编号 4687 展板 7 时间 4/21 09:00–12:00 区域 Section 21 主讲 Thales Nepomuceno, PhD
分会场 Insights into Genomic Instability
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Nicholas Woods1, Thales Nepomuceno2, Rebekah Baskin3, Rafael Mesquita4, Volha Golubeva5, Xueli Li2, Nicholas Palermo6, John M. Koomen2, Alvaro N. Monteiro2

1UNMC Eppley Institute, F&P Buffett Cancer Center, Omaha, NE,2Moffitt Cancer Center, Tampa, FL,3Graduate Student, St. Jude Children's Research Hospital, Memphis, TN,4Federal University of Rio de Janeiro, Rio de Janeiro, Brazil,5Ohio State University, Columbus, OH,6University of Nebraska, Omaha, NE

摘要 Abstract

中文摘要
蛋白质模块化结构域对细胞响应胞内及胞外信号至关重要,可促进动态多蛋白复合物应答特定刺激而组装。BRCA1 C端(BRCT)结构域存在于人类蛋白质组的23种蛋白中,包含46个独立的BRCT模块,组织为14个单体、16个串联体和一个由BRCT功能单元构成的四联体。BRCT单体由四条平行beta折叠构成的中央核心组成,一侧由两条alpha螺旋侧翼、另一侧由一条alpha螺旋侧翼。BRCT结构域是一种多功能的蛋白质模块化结构域,已成为维持基因组完整性中信号的整合者。我们此前绘制了七个串联BRCT结构域(tBRCT)的蛋白质—蛋白质相互作用网络,揭示了DNA损伤信号传导中此前未知的组分。在此,我们在既往工作基础上,呈现了一个以BRCT为中心的综合性人类蛋白质—蛋白质相互作用网络(PPN),涵盖组织为多种结构域架构的46个BRCT结构域。该网络通过整合文献筛选、酵母双杂交(Y2H)筛选以及串联亲和纯化偶联质谱(TAP-MS)的数据确定,包含3,162个经严格筛选的BRCT依赖性相互作用及1,672种独特的人类蛋白。含BRCT的蛋白PAXIP1(又称PTIP)对通过非同源末端连接进行的DNA双链断裂修复至关重要。PAXIP1具有独特的结构组织,包含三个tBRCT结构域,呈现出一组独特的PPN。有趣的是,最后四个BRCT结构域在人类蛋白质组中形成一个独特的四联体(qBRCT),可结合一组在任一单独tBRCT中均未观察到的蛋白。这些数据表明,不同的相互作用伙伴可能由不同组合的高阶BRCT结构域组织所招募,以组装分子间或分子内复合物,从而适应响应基因毒性刺激的组合式相互作用。此外,我们在19个BRCT结构域上定位了62个独特的磷酸化位点。我们发现PAXIP1 qBRCT磷酸化改变了其与gH2AX的结合,通过调节BRCT介导的配体识别提供了一个额外的调控层次。此处绘制的BRCT PPN资源提供了对人类蛋白质组中这些模块化蛋白质结构域的全面分析,有助于理解癌症及其对基因毒性临床治疗的反应。
查看英文原文 English abstract
Protein modular domains are critical for the cellular response to intra- and extracellular signaling, facilitating the assembly of dynamic multi-protein complexes in response to specific stimuli. The BRCA1 C-Terminal (BRCT) domain is present in 23 proteins in the human proteome, containing 46 individual BRCT modules organized as 14 singletons, 16 tandems, and one quartet of BRCT functional units. The BRCT singleton consists of a central core of four parallel beta sheets flanked by two alpha helices on one side and one alpha helix on the opposite side. The BRCT domain is a versatile protein-modular domain that has emerged as an integrator of signals in maintaining genomic integrity. We previously charted the protein-protein interaction network of seven tandem BRCT domains (tBRCT), revealing previously unknown components in DNA damage signaling. Here, we present a comprehensive BRCT-centered human protein-protein interaction network (PPN) comprising 46 BRCT domains organized into various domain architectures, building on our previous work. This network was determined by integrating data from literature curation, yeast two-hybrid (Y2H) screens, and tandem affinity purification coupled to mass spectrometry (TAP-MS) and comprises 3,162 highly curated BRCT-dependent interactions and 1,672 unique human proteins. The BRCT-containing protein PAXIP1 (also known as PTIP) is critical for DNA double-strand break repair by non-homologous end joining. PAXIP1 has a distinctive structural organization, containing three tBRCT domains, which present a unique set of PPN. Interestingly, the last four BRCT domains form a unique quartet (qBRCT) in the human proteome, binding to a set of proteins not observed in either of the tBRCTs alone. These data indicate that distinct interacting partners may be recruited by different combinations of higher-order BRCT domain organization to assemble inter- or intramolecular complexes, accommodating combinatorial interactions in response to genotoxic stimuli. Moreover, we mapped 62 unique phosphorylation sites at 19 BRCT domains. We identified that PAXIP1 qBRCT phosphorylation alters its binding to gH2AX, providing an additional layer of regulation by modulating BRCT-mediated ligand recognition. The BRCT PPN resource charted here provides a comprehensive analysis of these modular protein domains in the human proteome, contributing to an understanding of cancer and its response to genotoxic clinical therapies.
利益披露 Disclosure
T. Nepomuceno, None.. R. Mesquita, None.. V. Golubeva, None.. X. Li, None.. N. Palermo, None.

← 返回 AACR 2026 检索